MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

March 31, 2012

Conditions
Castrate Resistant Prostate Cancer (CRPC)
Interventions
BIOLOGICAL

BPX-101

Vaccine

DRUG

AP1903

Activating agent, infusion

Trial Locations (1)

77030

University of Texas Health Science Center Houston, CRU, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

The University of Texas Health Science Center, Houston

OTHER

collaborator

Memorial Hermann Hospital

OTHER

collaborator

Baylor College of Medicine

OTHER

lead

Bellicum Pharmaceuticals

INDUSTRY